Contact Us
Drug Search Results
More Filters [+]

CLE-400

Alternative Names: CLE-400, CLE400, CLE 400
Latest Update: 2024-12-24
Latest Update Note: Clinical Trial Update

Product Description

Clexio is developing CLE-400, a topical gel formulation containing a non-opioid, non-steroid, analgesic compound, to treat patients suffering from peripheral neuropathic pain. CLE-400 is a new investigational drug that has not been approved for commercial distribution. (Sourced from: https://www.clexio.com/pipeline/cle-400-pain/)

Mechanisms of Action: ADRA2 Agonist

Novel Mechanism: Yes

Modality: N/A

Route of Administration: Topical

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Clexio Biosciences
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CLE-400

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Back Pain|Chronic Pain|Pruritus

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
CLE400-NP-201

P2

Completed

Pruritus|Chronic Pain|Back Pain

2024-11-06

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions